MERCK
25.11.2021 09:03:01 CET | Business Wire | Press release
After two years of the Covid-19 pandemic, results from a European survey reveal that more than half of Europeans rate their physical health as good or very good - with a quarter of respondents reducing their alcohol and drug consumption and one in five saying they eat a healthier diet. Although 45% of Europeans rate their mental health as good or very good, 23% of the youngest (18-29 years old) say they have needed psychological help during the pandemic.
These are just some of the major findings from the "Merck Survey: Europeans' perception of health two years after the start of Covid 19" ; a survey of 6,000 people aged 18 to 65 from ten countries (Germany, Belgium, Spain, France, Italy, Poland, Portugal, United Kingdom, Czech Republic and Switzerland) that the science and technology company Merck carried out with the technical support of GAD3.
"This pandemic has triggered the biggest health, social and economic crisis in almost a century and - from the perspective of having overcome the most critical months of it - in Merck we wanted to know its impact on the health and lifestyle of Europeans,” says Marieta Jiménez, Senior Vice President of Merck Healthcare in Europe. " We believe that only by getting closer and asking people what they feel, think and need can we provide answers to the different health challenges. A healthy society is the basis for building a stronger, safer and more prosperous society," she adds.
The survey shows that Europeans (especially Italians, Spaniards and Portuguese) consider that the pandemic has helped them to talk openly in their personal and professional environment about their physical and mental health. In addition, one in three Europeans say that it has improved family coexistence and feelings of solidarity (34% and 33% respectively). Family co-existence was reported as a particular benefit by more Spaniards ad Czechs than in any other European country surveyed (42% and 45% respectively).
In contrast, the survey emphasizes the weight of emotional problems arising from the pandemic. The results show that 26% of all Europeans have developed a fear of physical contact with other people and 23% of young people surveyed have needed psychological help . Stress and anxiety, followed by fear and uncertainty, are the feelings that have affected more than a third of Europeans (38% and 33%, respectively).
When compared to the European average, stress and anxiety have affected countries such as Spain, Poland and Portugal more, while fear and uncertainty have particularly affected Spain, Italy and Portugal. Germany, Spain, the UK and Poland are the countries most affected by loneliness.
New times, new habits
The pandemic has also boosted the use of new health technologies. The Merck survey concludes that seven out of ten Europeans say they are comfortable or increasingly comfortable with telemedicine. Although most Europeans continue to prefer face-to-face consultations after the health crisis, people from Portugal, France and Italy reported a current preference for telemedicine vs. face-to-face consultations.
The survey further reveals that almost a quarter (24%) of Europeans say they have reduced their alcohol and drug consumption and one in five say they now eat a healthier diet.
Furthermore, only one in ten Europeans have postponed their plans to build or grow a family after the pandemic. People from the Czech Republic and Italy have postponed their intention to have children the most after the pandemic (14% and 15% respectively).
High recognition for health professionals
The study also probes opinions about the work of different health and science professionals during the pandemic. All countries recognize the good work of health personnel. In fact, 70% of Europeans rate the work of health workers and researchers as good or very good. Even so, it is worth noting that the performance of pharmacists during the pandemic was the most highly rated in all countries (compared to doctors, nurses, scientists and researchers) and they were the most highly rated in countries such as Spain and the Czech Republic.
When asked about what should be improved in the health system, 6 out of 10 European countries surveyed agree on the need to invest more in preventive medicine and public health, followed by primary care and mental health. Germans prefer researching new medicines over all other areas, while the British attach greater importance to mental health and the Poles call for greater primary care along with the Spanish.
Which diseases do Europeans fear the most?
In addition, the “ Merck Survey: Europeans' perception of health two years after the start of Covid 19” also points out that 75% of Europeans think that the health crisis has affected the normal course of cancer treatments. Cancer is the most feared disease in the wake of the pandemic, followed by neurodegenerative diseases, such as Alzheimer's or Parkinson's, and cardiovascular diseases.
“We are living unprecedented times and as a curious company we need to prioritize more than ever the value of science and professionals working in the service of health," emphasizes François Feig, Senior Vice President Mid Europe Healthcare at Merck. “This ambitious survey sheds light on the feelings of Europeans about their health after two years of living with Covid and I believe that this information will allow all of us who put our efforts in the service of people's health and well-being to better understand their needs . ”
To access the Merck Survey, please follow this link .
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005676/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 2615.5.2026 14:00:00 CEST | Press release
LYCRA FUSION™ Fiber for Personal Care Applications Debuts The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515514441/en/ Join The LYCRA Company and Dukane at INDEX™ 26 in Geneva, as they showcase their latest advances in ultrasonic bonding for nonwovens, including new LYCRA FUSION™ fiber for personal care that delivers superior snapback. Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrason
Vecima to Highlight Next-Generation 50G-PON, DOCSIS® 4.0 vCMTS, AI & Automation, and Monetizable Streaming at ANGA COM 202615.5.2026 13:45:00 CEST | Press release
Vecima Networks Inc. (TSX: VCM) will highlight its leadership in next-generation broadband at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS® 4.0 access, and scalable fiber solutions. Anchored by the Entra® vCMTS platform, Automation, and All-PON™ innovations, Vecima is enabling operators to automate operations, improve reliability, and accelerate the evolution to converged cable and fiber networks. Delivering on Next-Generation PON With Entra All-PON™, Vecima is enabling future-ready fiber networks with a straightforward migration path from today’s 10G technologies to 50G-PON, ensuring long-term scalability and investment protection. The new Entra EPS1650 All-PON Shelf supports 50G-PON, XGS-PON, 10G-EPON, GPON, and EPON services. As a follow-on to Vecima's industry-first demonstration of a single port supporting 50G ITU PON and 10G-EPON in a Remote OLT, the EPS1650 brings that same single-port investment-protection path to GPON and XGS-PON operators in a
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
